<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554514</url>
  </required_header>
  <id_info>
    <org_study_id>LDrituximab</org_study_id>
    <secondary_id>1U54HL112303-01</secondary_id>
    <nct_id>NCT01554514</nct_id>
  </id_info>
  <brief_title>Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura</brief_title>
  <official_title>Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J. Evan Sadler, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by small blood clots
      throughout the body that can damage major organs and cause death. TTP is treated with plasma
      exchange (also called &quot;plasmapheresis&quot;). Patients who do not respond initially to plasma
      exchange often are helped by later treatment with rituximab. The purpose of this study is to
      see whether combining low doses of rituximab with plasma exchange will help patients get
      better sooner and reduce the chance of getting TTP again.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot safety/efficacy study of adjuvant low dose rituximab (100 mg/week x 4 doses)
      plus standard plasma exchange and corticosteroids for the treatment of thrombotic
      thrombocytopenic purpura (TTP) with severe ADAMTS13 deficiency. Results for study subjects
      will be compared to historical controls treated initially with plasma exchange and
      corticosteroids. This study proposes to test the hypothesis that adjuvant low dose rituximab
      may decrease the incidence of a composite primary endpoint (exacerbations or refractory
      disease) in acquired TTP with severe ADAMTS13 deficiency. A novel ADAMTS13 assay will be used
      to identify patients with TTP and severe ADAMTS13 deficiency for enrollment, and to assess
      the utility of ADAMST13 as a biomarker for response to therapy and prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of the composite primary outcome of exacerbation or refractory TTP</measure>
    <time_frame>60 days</time_frame>
    <description>Exacerbation is recurring TTP ≤30 days after a Treatment Response (normal platelet count for 2 days) and discontinuation of plasma exchange. Refractory TTP is failure to achieve a Treatment Response by day 28, or failure to achieve a Durable Treatment Response (lasting at least 30 days) by day 60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Durable Treatment Response</measure>
    <time_frame>60 days</time_frame>
    <description>Treatment Response is 2 consecutive days with platelet count ≥150, 000/µL Durable Treatment Response is a Treatment Response that persists for ≥30 days after discontinuation of plasma exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to Durable Treatment Response</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse is recurring TTP &gt;30 days after Treatment Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to Relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of death will be assessed at 4 weeks, 1 year and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence, type and severity of treatment-related adverse events will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>low dose rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this is a single-arm trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>rituximab intravenously 100 mg every week for four doses</description>
    <arm_group_label>low dose rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or greater

          2. Diagnosis of suspected thrombotic thrombocytopenic purpura (TTP)

               1. Platelet count of &lt; 80,000 for newly diagnosed patients and &lt; 120,000 for
                  relapsed patients

               2. Microangiopathic hemolytic anemia with RBC fragmentation

               3. LDH &gt;1 x ULN

          3. Subjects who will receive treatment for TTP with plasma exchange

          4. Subjects who have not started the 5th plasma exchange

          5. Plasma ADAMTS13 activity &lt;10%

        Exclusion Criteria:

          1. Treatment for TTP within the past 2 months

          2. Severe active infection indicated by sepsis (requirement for pressors with or without
             positive blood cultures) or clinical evidence of enteric infection with E. coli
             O157:H7 or related organism

          3. Currently under treatment for cancer (subjects with localized skin carcinoma will be
             accepted)

          4. Microangiopathic hemolytic anemia due to a mechanical heart valve

          5. Severe hypertension, as defined by systolic BP &gt;180 AND diastolic BP &gt;120, or
             papilledema

          6. Organ or stem cell transplant

          7. Use of calcineurin inhibitors (sirolimus, tacrolimus, cyclosporin A) within 6 months
             prior to diagnosis of TTP

          8. Disseminated intravascular coagulation as defined by:

             a. INR &gt;2.0 (unrelated to anticoagulation, unresponsive to Vitamin K) or b. Fibrinogen
             &lt;100 mg/dl

          9. Pregnancy

         10. Known congenital TTP.

         11. Rituximab within the previous year.

         12. HIV history or positive serology

         13. History of hepatitis B or positive serology for HBsAg or Anti-HBc

         14. Persistent or unexplained platelet count below 150,000/μL within 3 months of current
             TTP presentation

         15. Hypersensitivities or allergies to murine and/or humanized antibodies

         16. Current participation in trials of investigational therapies or devices, other than
             central catheters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J E Sadler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason</last_name>
      <phone>404-778-4334</phone>
      <email>shannon.gleason@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ana Antun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martha Arellano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonard T Heffner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amelia Langston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vamsi Kota, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaid Al-Kadhimi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Rodrigues</last_name>
      <phone>617-667-1939</phone>
      <email>aerodrig@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Logan</last_name>
      <phone>617-667-5984</phone>
      <email>eklogan@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Zwicker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Bauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayad Hamdan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Uhlmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Weinstock, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanetta Worthy</last_name>
      <phone>314-362-9998</phone>
      <email>VWORTHY@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Nieters, RN, BSN</last_name>
      <phone>314-362-3371</phone>
      <email>nietersp@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>J E Sadler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morey Blinder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elaine Majerus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Oh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Sanfilippo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Eby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Ley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Link, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Muia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suresh Vedantham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Tollefsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brenda Grossman, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sana Saif Ur Rehman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhou Amy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin H Byrne</last_name>
      <phone>919-681-2668</phone>
      <email>kristin.byrne@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Betty H Thames, RN, BSN</last_name>
      <phone>919-681-9564</phone>
      <email>elizabeth.thames@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ara Metjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas L Ortel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nirmish Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gowthami Arepally, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toyosi Onwuemene, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P; French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012 Jan;40(1):104-11. doi: 10.1097/CCM.0b013e31822e9d66.</citation>
    <PMID>21926591</PMID>
  </reference>
  <results_reference>
    <citation>Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol. 2010 Jan;91(1):36-45. doi: 10.1007/s12185-009-0478-z. Review.</citation>
    <PMID>20058208</PMID>
  </results_reference>
  <results_reference>
    <citation>Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013 Mar;11(3):481-90. doi: 10.1111/jth.12114.</citation>
    <PMID>23279219</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol. 2004 Oct;77(2):171-6.</citation>
    <PMID>15389904</PMID>
  </results_reference>
  <results_reference>
    <citation>Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, Söhngen D. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002 Oct;71(2):105-8.</citation>
    <PMID>12353309</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>J. Evan Sadler, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>ADAMTS13</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Thrombotic thrombocytopenic purpura</keyword>
  <keyword>TTP</keyword>
  <keyword>Plasma exchange</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

